Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

After a median follow-up of 20.9 months, patients on 177Lu-PSMA-617 had radiographic progression-free survival (PFS) of 8.7 months, compared to 3.4 months in the control group, and overall ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration ...